| Lin SJ |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=2.604 ------>paper_class3=2 ------>paper_class2=1 ------>vol=14 ------>confirm_bywho=amel ------>insert_bywho=lmyang ------>Jurnal_Rank=34.1 ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=1176 ------>medlineContent= ------>unit=G0100 ------>insert_date=20081119 ------>iam=4 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=391 ------>journal_name=Bioorg. Med. Chem. Lett. ------>paper_name=Abeta Aggregation inhibitors. Part I: Synthesis and biological activity of phenylazo benzenesulfonamides ------>confirm_date=20081121 ------>tch_id=078012 ------>pmid=14980659 ------>page1=1173 ------>fullAbstract=Phenylazo benzenesulfonamides were designed and synthesized as beta-amyloid (Abeta40) fibril assembly inhibitors, and evaluated for inhibition of Abeta40 aggregation and neurotoxicity using rat cortical neurons. Compound 2 (LB-152) was the most potent compound in this study, and the para-NMe(2) group on the end of the phenylazo moiety may play an important role in preventing Abeta40 fibril formation. LB-152 provides a new lead for further development of potential beta-amyloid aggregation inhibitors to treat AD. ------>tmu_sno=None ------>sno=19329 ------>authors2=Shiao YJ ------>authors3=Chi CW ------>authors4=Yang LM ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Lin SJ ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Abeta aggregation inhibitors. Part 1: Synthesis and biological activity of phenylazo benzenesulfonamides. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2004 ------>submit_flag=None ------>publish_month=1 |